The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions

Breast Journal

Volumn 14, Issue 5, 2008, Pages 476-482

  Davidson, Ben ^a,b,c   Dong, Hiep Phuc ^b   Holth, Arild ^b   Berner, Aasmund ^b   Risberg, Björn ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Rikshospitalet Medical Center   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Breast carcinoma; Chemokines receptors; Effusions; Immune response

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4;

ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; MACROPHAGE; METASTASIS; MONOCYTE; OVARY CARCINOMA; PERICARDIAL EFFUSION; PERITONEUM EXUDATE; PLEURA EFFUSION; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; BREAST NEOPLASMS; COHORT STUDIES; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RECEPTORS, CXCR4; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 51349089229     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2008.00625.x     Document Type: Article

References (35)

1. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002 12 : 113 20.
2. Homey B, Müller A, Zlotnik A. Chemokines: agents for immunotherapy of cancer. Nat Rev Immunol 2002 2 : 175 84.
3. Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998 65 : 108 13.
4. Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute. Cancer 1995 76 : 1377 87.
5. Dieterich M, Goodman SN, Rojas-Corona RR, Emralino AB, Jimenez-Joseph D, Sherman ME. Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 1994 38 : 945 52.
6. Banerjee AK, Willetts I, Robertson JF, Blamey RW. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 1994 20 : 33 6.
7. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004 64 : 8604 12.
8. Liang Z, Wu T, Lou H, et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004 64 : 4302 8.
9. Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 2003 63 : 4801 4.
10. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005 121 : 335 48.
11. Toulza F, Eliaou JF, Pinet V. Breast tumor cell soluble factors induce monocytes to produce angiogenic but not angiostatic CXC chemokines. Int J Cancer 2005 115 : 429 36.
12. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003 63 : 8360 5.
13. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004 6 : 459 69.
14. Cabioglu N, Summy J, Miller C, et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005 65 : 6493 7.
15. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004 6 : 17 32.
16. Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 2005 14 : 360 7.
17. Cabioglu N, Yazici MS, Arun B, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 2005 11 : 5686 93.
18. Salvucci O, Bouchard A, Baccarelli A, et al. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2006 97 : 275 83.
19. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z. Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 2006 346 : 252 8.
20. Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006 17 : 945 51.
21. Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004 10 : 7466 74.
22. Dong HP, Bunkholt Elstrand M, Holth A, et al. NK and B cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006 125 : 451 8.
23. Davidson B, Dong HP, Holth A, Berner A, Risberg B. Chemokine receptors are infrequently expressed in malignant or benign mesothelial cells. Am J Clin Pathol 2007 127 : 752 9.
24. Davidson B, Nielsen S, Christensen J, et al. The role of Desmin and N-cadherin in effusion cytology. A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001 25 : 1405 12.
25. Davidson B, Dong HP, Berner A, et al. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol 2002 118 : 85 92.
26. Dong HP, Holth A, Berner A, Davidson B, Risberg B. Flow cytometric immunphenotyping of epithelial cancer cells in effusions-Technical considerations and pitfalls. Cytometry B Clin Cytom 2007 72B : 332 43.
27. Davidson B, Konstantinovsky S, Nielsen S, et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients-a novel model for tumor progression. Clin Cancer Res 2004 10 : 7335 46.
28. Davidson B, Reich R, Lazarovici P, Flørenes VA, Nielsen S, Nesland JM. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 2004 83 : 119 28.
29. Konstantinovsky S, Nielsen S, Vyberg M, et al. Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res Treat 2005 94 : 71 80.
30. Davidson B, Konstantinovsky S, Kleinberg L, et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 2006 102 : 453 61.
31. Yoneda J, Kuniyasu H, Crispens MA, et al. Expression of angiogenesis-related genes and progression in human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998 90 : 447 54.
32. Davidson B, Goldberg I, Kopolovic J, et al. Expression of angiogenesis-related genes in ovarian carcinoma-a clinicopathologic study. Clin Exp Metastasis 2000 18 : 501 7.
33. Pupa SM, Bufalino R, Invernizzi AM, et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 1996 14 : 85 94.
34. Menard S, Tomasic G, Casalini P, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997 3 : 817 9.
35. Georgiannos SN, Renaut A, Goode AW, Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery 2003 134 : 827 34.